NSCLC has higher expression of the protein kinase C iota (PKCι), and treatment with the PAK1 inhibitor (IPA-3) and the PKCi inhibitor (auranofin) is highly effective in EGFR and KRAS mutant NSCLC [47]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.